Dossier assessment
Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with a moderate to severe episode of major depressive disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.
Project details
- Project no.
- A21-25
- Commission
- Commission awarded on 04.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Mental and emotional wellbeing
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Esketamine (depression) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Esketamine (depression, acute treatment) - Addendum to Commission A21-25
Status: Commission completed